7 Apr 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
27 Mar 2024 Date | | - Cons. EPS | - EPS |
25 Mar 2024 Date | | - Cons. EPS | - EPS |
7 Apr 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
27 Mar 2024 Date | | - Cons. EPS | - EPS |
25 Mar 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | David Apelian CEO | NASDAQ (NMS) Exchange | 28249U105 Cusip |
US Country | 56 Employees | - Last Dividend | 8 Jan 2024 Last Split | 30 Jan 2014 IPO Date |
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare and ultra-rare diseases. Operating both within the United States and internationally, the company is driven by a mission to address unmet medical needs in conditions that are often overlooked. Founded in 2008 and based in Palo Alto, California, Eiger BioPharmaceuticals has established itself as a key player in the realm of rare disease therapy development.
The company's product pipeline is diverse and focused on targeted therapies that promise to provide significant clinical benefits for patients suffering from rare diseases. These include: